Table 1. Cetuximab sensitivity and genetic profile for 26 CRC PDX models.

Response	Model ID	ΔT/ΔC%	AKT1L52R	BRAFV600E	KRAS G12D/V/C	KRAS A146T	KRAS Q61H	KRASG13D	NRASQ61R	PIK3CAE545G/KQ546L
Responder	CR2110	−48%	WT	WT	WT	WT	WT	WT	WT	WT
	CR0231	−13%	WT	WT	WT	WT	WT	G13D	WT	WT
	CR2502	−9%	WT	WT	WT	WT	WT	WT	WT	WT
	CR0170	−7%	WT	WT	WT	WT	WT	WT	WT	WT
	CR0196	−6%	WT	WT	WT	WT	WT	WT	WT	WT
	CR2520	1%	WT	WT	WT	WT	WT	G13D	WT	WT
	CR0588	11%	WT	WT	WT	WT	WT	G13D	WT	WT
	CR0193	16%	WT	WT	WT	WT	WT	G13D	WT	WT
Non-/partial responder	CR0047	27%	WT	WT	G12C	WT	WT	WT	WT	E545K
	CR0560	28%	WT	WT	WT	WT	WT	WT	WT	WT
	CR0205	34%	WT	WT	WT	WT	WT	WT	WT	WT
	CR0150	43%	WT	WT	G12D	WT	WT	WT	WT	WT
	CR1530	52%	WT	WT	WT	WT	Q61H	WT	WT	E545K
	CR2226	62%	WT	WT	WT	WT	WT	G13D	WT	WT
	CR1519	67%	WT	WT	WT	WT	Q61H	WT	WT	WT
	CR0245	69%	WT	WT	WT	A146T	WT	WT	WT	WT
	CR1554	69%	WT	WT	G12V	WT	WT	WT	WT	WT
	CR0004	75%	WT	V600E	WT	WT	WT	WT	WT	E545K
	CR1245	76%	WT	WT	G12D	WT	WT	WT	WT	WT
	CR0012	81%	WT	WT	WT	WT	WT	G13D	WT	WT
	CR0455	86%	WT	WT	G12D	WT	WT	WT	WT	WT
	CR1574	88%	WT	WT	WT	WT	WT	WT	Q61R	Q546L
	CR1795	94%	WT	WT	WT	WT	WT	WT	WT	WT
	CR0029	95%	WT	V600E	WT	WT	WT	WT	WT	WT
	CR0146	118%	WT	WT	WT	WT	WT	WT	WT	E545G
	CR1744	129%	L52R	WT	WT	WT	WT	WT	WT	WT
	CR0010	158%	WT	WT	WT	A146T	WT	WT	WT	E545K